John Oyler, BeiGene CEO (Endpoints News, PharmCube)
August 2, 2023 02:46 PM EDT
Pharma

BeiGene's BTK in­hibitor brings in $308M, dri­ves Q2 earn­ings with 46% in­crease from Q1

Katherine Lewin

News Reporter

BeiGene saw huge growth in its BTK in­hibitor Brukin­sa this quar­ter, mark­ing a 139% in­crease from the same time last year and a 46% in­crease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times